Clinical Trials Browser

Lung Neoplasms

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

22 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04504071 2025-09-08

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Phase 2 Active not recruiting

30 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT04027647 2025-06-12

Phase 2 Study of Dacomitinib in NSCLC

Phase 2 Active not recruiting

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04946968 2025-06-11

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Phase 2 Active not recruiting

24 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04155541 2025-05-23

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Completed

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03755102 2025-05-15

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Phase EARLY_PHASE1 Completed

17 enrolled

Thoracic

Lung Neoplasms

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04511533 2024-04-05

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Phase 4 Completed

101 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01000025 2023-08-22

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Phase 3 Completed

720 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05271916 2023-04-19

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Phase 1/2 Recruiting

140 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04811001 2023-02-21

CAPLAND

Phase 2 Unknown

170 enrolled

Thoracic

NSCLC

NCT04768491 2021-02-24

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Unknown

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04675008 2021-01-05

Central Nervous System(CNS) Efficacy of Dacomitinib

Phase 2 Unknown

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04575415 2020-10-20

BELLA

Unknown

272 enrolled

Thoracic

NSCLC

NCT04339829 2020-04-09

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00548093 2019-05-21

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2 Completed

66 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01465802 2019-01-09

ARCHER 1042

Phase 2 Completed

236 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01360554 2017-05-24

ARCHER 1009

Phase 3 Completed

878 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00769067 2015-10-07

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase 2 Completed

188 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Clinical Trials

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Phase 2 Study of Dacomitinib in NSCLC

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

DELINOR

ERIS

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

CAPLAND

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Central Nervous System(CNS) Efficacy of Dacomitinib

BELLA

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

ARCHER 1042

ARCHER 1009

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen